eucast Search Results


eucast  (Clinical and Laboratory Standards Institute)
90
Clinical and Laboratory Standards Institute eucast
Eucast, supplied by Clinical and Laboratory Standards Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eucast/product/Clinical and Laboratory Standards Institute
Average 90 stars, based on 1 article reviews
eucast - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
eucast esbl disk kit  (Liofilchem)
90
Liofilchem eucast esbl disk kit
Eucast Esbl Disk Kit, supplied by Liofilchem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eucast esbl disk kit/product/Liofilchem
Average 90 stars, based on 1 article reviews
eucast esbl disk kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
romania gp 1 eucast micronaut plates  (Bruker Corporation)
90
Bruker Corporation romania gp 1 eucast micronaut plates
Romania Gp 1 Eucast Micronaut Plates, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/romania gp 1 eucast micronaut plates/product/Bruker Corporation
Average 90 stars, based on 1 article reviews
romania gp 1 eucast micronaut plates - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
e-test eucast  (Koehler Instrument)
90
Koehler Instrument e-test eucast
Susceptibility of Aspergillus fumigatus to azole antifungal agents.
E Test Eucast, supplied by Koehler Instrument, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/e-test eucast/product/Koehler Instrument
Average 90 stars, based on 1 article reviews
e-test eucast - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
disk diffusion 15μg azithromycin using eucast-and clsi potency neo-sensitabstm  (Diagnostica Stago)
90
Diagnostica Stago disk diffusion 15μg azithromycin using eucast-and clsi potency neo-sensitabstm
If the patient still had diarrhoea the patient was offered to participate in the clinical trial. At day 1 the patient met the principal-investigator in an outpatient setting and was randomized to either <t>azithromycin</t> or placebo 500 mg once-daily dose for three days for the treatment of diarrhoea. Moreover, the patient was asked to deliver a blood sample (CRP and leukocytes) as well as a saliva sample. During the follow-up period of ten days the patient had to fill in a questionnaire on daily basis regarding diarrheic symptoms. At day ten the patient was contacted by telephone by the principal-investigator and if the patient stated ongoing diarrheic symptoms (no effect of study treatment; azithromycin or placebo) the patient was offered another ten-day study period and treatment with cross-over study medication (azithromycin or placebo), also double-blinded. Finally, the patient was asked to deliver a saliva sample as well as a stool sample for an ongoing diagnosis of C . concisus infection.
Disk Diffusion 15μg Azithromycin Using Eucast And Clsi Potency Neo Sensitabstm, supplied by Diagnostica Stago, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/disk diffusion 15μg azithromycin using eucast-and clsi potency neo-sensitabstm/product/Diagnostica Stago
Average 90 stars, based on 1 article reviews
disk diffusion 15μg azithromycin using eucast-and clsi potency neo-sensitabstm - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
eucast broth microdilution method  (National Reference Center for Legionella)
90
National Reference Center for Legionella eucast broth microdilution method
If the patient still had diarrhoea the patient was offered to participate in the clinical trial. At day 1 the patient met the principal-investigator in an outpatient setting and was randomized to either <t>azithromycin</t> or placebo 500 mg once-daily dose for three days for the treatment of diarrhoea. Moreover, the patient was asked to deliver a blood sample (CRP and leukocytes) as well as a saliva sample. During the follow-up period of ten days the patient had to fill in a questionnaire on daily basis regarding diarrheic symptoms. At day ten the patient was contacted by telephone by the principal-investigator and if the patient stated ongoing diarrheic symptoms (no effect of study treatment; azithromycin or placebo) the patient was offered another ten-day study period and treatment with cross-over study medication (azithromycin or placebo), also double-blinded. Finally, the patient was asked to deliver a saliva sample as well as a stool sample for an ongoing diagnosis of C . concisus infection.
Eucast Broth Microdilution Method, supplied by National Reference Center for Legionella, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eucast broth microdilution method/product/National Reference Center for Legionella
Average 90 stars, based on 1 article reviews
eucast broth microdilution method - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
eucast breakpoints  (Clinical and Laboratory Standards Institute)
90
Clinical and Laboratory Standards Institute eucast breakpoints
If the patient still had diarrhoea the patient was offered to participate in the clinical trial. At day 1 the patient met the principal-investigator in an outpatient setting and was randomized to either <t>azithromycin</t> or placebo 500 mg once-daily dose for three days for the treatment of diarrhoea. Moreover, the patient was asked to deliver a blood sample (CRP and leukocytes) as well as a saliva sample. During the follow-up period of ten days the patient had to fill in a questionnaire on daily basis regarding diarrheic symptoms. At day ten the patient was contacted by telephone by the principal-investigator and if the patient stated ongoing diarrheic symptoms (no effect of study treatment; azithromycin or placebo) the patient was offered another ten-day study period and treatment with cross-over study medication (azithromycin or placebo), also double-blinded. Finally, the patient was asked to deliver a saliva sample as well as a stool sample for an ongoing diagnosis of C . concisus infection.
Eucast Breakpoints, supplied by Clinical and Laboratory Standards Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eucast breakpoints/product/Clinical and Laboratory Standards Institute
Average 90 stars, based on 1 article reviews
eucast breakpoints - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
eucast  (Radboud University)
90
Radboud University eucast
If the patient still had diarrhoea the patient was offered to participate in the clinical trial. At day 1 the patient met the principal-investigator in an outpatient setting and was randomized to either <t>azithromycin</t> or placebo 500 mg once-daily dose for three days for the treatment of diarrhoea. Moreover, the patient was asked to deliver a blood sample (CRP and leukocytes) as well as a saliva sample. During the follow-up period of ten days the patient had to fill in a questionnaire on daily basis regarding diarrheic symptoms. At day ten the patient was contacted by telephone by the principal-investigator and if the patient stated ongoing diarrheic symptoms (no effect of study treatment; azithromycin or placebo) the patient was offered another ten-day study period and treatment with cross-over study medication (azithromycin or placebo), also double-blinded. Finally, the patient was asked to deliver a saliva sample as well as a stool sample for an ongoing diagnosis of C . concisus infection.
Eucast, supplied by Radboud University, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eucast/product/Radboud University
Average 90 stars, based on 1 article reviews
eucast - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
discs according to eucast concentrations  (Mast Diagnostica GmbH)
90
Mast Diagnostica GmbH discs according to eucast concentrations
If the patient still had diarrhoea the patient was offered to participate in the clinical trial. At day 1 the patient met the principal-investigator in an outpatient setting and was randomized to either <t>azithromycin</t> or placebo 500 mg once-daily dose for three days for the treatment of diarrhoea. Moreover, the patient was asked to deliver a blood sample (CRP and leukocytes) as well as a saliva sample. During the follow-up period of ten days the patient had to fill in a questionnaire on daily basis regarding diarrheic symptoms. At day ten the patient was contacted by telephone by the principal-investigator and if the patient stated ongoing diarrheic symptoms (no effect of study treatment; azithromycin or placebo) the patient was offered another ten-day study period and treatment with cross-over study medication (azithromycin or placebo), also double-blinded. Finally, the patient was asked to deliver a saliva sample as well as a stool sample for an ongoing diagnosis of C . concisus infection.
Discs According To Eucast Concentrations, supplied by Mast Diagnostica GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/discs according to eucast concentrations/product/Mast Diagnostica GmbH
Average 90 stars, based on 1 article reviews
discs according to eucast concentrations - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
the following eucast breakpoints were applied  (Merck & Co)
90
Merck & Co the following eucast breakpoints were applied
If the patient still had diarrhoea the patient was offered to participate in the clinical trial. At day 1 the patient met the principal-investigator in an outpatient setting and was randomized to either <t>azithromycin</t> or placebo 500 mg once-daily dose for three days for the treatment of diarrhoea. Moreover, the patient was asked to deliver a blood sample (CRP and leukocytes) as well as a saliva sample. During the follow-up period of ten days the patient had to fill in a questionnaire on daily basis regarding diarrheic symptoms. At day ten the patient was contacted by telephone by the principal-investigator and if the patient stated ongoing diarrheic symptoms (no effect of study treatment; azithromycin or placebo) the patient was offered another ten-day study period and treatment with cross-over study medication (azithromycin or placebo), also double-blinded. Finally, the patient was asked to deliver a saliva sample as well as a stool sample for an ongoing diagnosis of C . concisus infection.
The Following Eucast Breakpoints Were Applied, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/the following eucast breakpoints were applied/product/Merck & Co
Average 90 stars, based on 1 article reviews
the following eucast breakpoints were applied - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
combined-disk test (cdt) proposed by eucast  (Liofilchem)
90
Liofilchem combined-disk test (cdt) proposed by eucast
If the patient still had diarrhoea the patient was offered to participate in the clinical trial. At day 1 the patient met the principal-investigator in an outpatient setting and was randomized to either <t>azithromycin</t> or placebo 500 mg once-daily dose for three days for the treatment of diarrhoea. Moreover, the patient was asked to deliver a blood sample (CRP and leukocytes) as well as a saliva sample. During the follow-up period of ten days the patient had to fill in a questionnaire on daily basis regarding diarrheic symptoms. At day ten the patient was contacted by telephone by the principal-investigator and if the patient stated ongoing diarrheic symptoms (no effect of study treatment; azithromycin or placebo) the patient was offered another ten-day study period and treatment with cross-over study medication (azithromycin or placebo), also double-blinded. Finally, the patient was asked to deliver a saliva sample as well as a stool sample for an ongoing diagnosis of C . concisus infection.
Combined Disk Test (Cdt) Proposed By Eucast, supplied by Liofilchem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/combined-disk test (cdt) proposed by eucast/product/Liofilchem
Average 90 stars, based on 1 article reviews
combined-disk test (cdt) proposed by eucast - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nccls/clsi guidelines  (Clinical and Laboratory Standards Institute)
90
Clinical and Laboratory Standards Institute nccls/clsi guidelines
If the patient still had diarrhoea the patient was offered to participate in the clinical trial. At day 1 the patient met the principal-investigator in an outpatient setting and was randomized to either <t>azithromycin</t> or placebo 500 mg once-daily dose for three days for the treatment of diarrhoea. Moreover, the patient was asked to deliver a blood sample (CRP and leukocytes) as well as a saliva sample. During the follow-up period of ten days the patient had to fill in a questionnaire on daily basis regarding diarrheic symptoms. At day ten the patient was contacted by telephone by the principal-investigator and if the patient stated ongoing diarrheic symptoms (no effect of study treatment; azithromycin or placebo) the patient was offered another ten-day study period and treatment with cross-over study medication (azithromycin or placebo), also double-blinded. Finally, the patient was asked to deliver a saliva sample as well as a stool sample for an ongoing diagnosis of C . concisus infection.
Nccls/Clsi Guidelines, supplied by Clinical and Laboratory Standards Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nccls/clsi guidelines/product/Clinical and Laboratory Standards Institute
Average 90 stars, based on 1 article reviews
nccls/clsi guidelines - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Susceptibility of Aspergillus fumigatus to azole antifungal agents.

Journal: Medical Mycology

Article Title: Aspergillus fumigatus —a systematic review to inform the World Health Organization priority list of fungal pathogens

doi: 10.1093/mmy/myad129

Figure Lengend Snippet: Susceptibility of Aspergillus fumigatus to azole antifungal agents.

Article Snippet: Koehler et al. , 2017 , E-test ® EUCAST , 75/77 (97.4%) , 76/77 (98.7%) , NS , NS.

Techniques: Modification

Susceptibility of Aspergillus fumigatus to echinocandins and amphotericin B.

Journal: Medical Mycology

Article Title: Aspergillus fumigatus —a systematic review to inform the World Health Organization priority list of fungal pathogens

doi: 10.1093/mmy/myad129

Figure Lengend Snippet: Susceptibility of Aspergillus fumigatus to echinocandins and amphotericin B.

Article Snippet: Koehler et al. , 2017 , E-test ® EUCAST , 75/77 (97.4%) , 76/77 (98.7%) , NS , NS.

Techniques:

If the patient still had diarrhoea the patient was offered to participate in the clinical trial. At day 1 the patient met the principal-investigator in an outpatient setting and was randomized to either azithromycin or placebo 500 mg once-daily dose for three days for the treatment of diarrhoea. Moreover, the patient was asked to deliver a blood sample (CRP and leukocytes) as well as a saliva sample. During the follow-up period of ten days the patient had to fill in a questionnaire on daily basis regarding diarrheic symptoms. At day ten the patient was contacted by telephone by the principal-investigator and if the patient stated ongoing diarrheic symptoms (no effect of study treatment; azithromycin or placebo) the patient was offered another ten-day study period and treatment with cross-over study medication (azithromycin or placebo), also double-blinded. Finally, the patient was asked to deliver a saliva sample as well as a stool sample for an ongoing diagnosis of C . concisus infection.

Journal: PLoS ONE

Article Title: Azithromycin vs. Placebo for the Clinical Outcome in Campylobacter concisus Diarrhoea in Adults: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

doi: 10.1371/journal.pone.0166395

Figure Lengend Snippet: If the patient still had diarrhoea the patient was offered to participate in the clinical trial. At day 1 the patient met the principal-investigator in an outpatient setting and was randomized to either azithromycin or placebo 500 mg once-daily dose for three days for the treatment of diarrhoea. Moreover, the patient was asked to deliver a blood sample (CRP and leukocytes) as well as a saliva sample. During the follow-up period of ten days the patient had to fill in a questionnaire on daily basis regarding diarrheic symptoms. At day ten the patient was contacted by telephone by the principal-investigator and if the patient stated ongoing diarrheic symptoms (no effect of study treatment; azithromycin or placebo) the patient was offered another ten-day study period and treatment with cross-over study medication (azithromycin or placebo), also double-blinded. Finally, the patient was asked to deliver a saliva sample as well as a stool sample for an ongoing diagnosis of C . concisus infection.

Article Snippet: Antimicrobial susceptibility testing to azithromycin was performed with use of disk diffusion with 15μg azithromycin using EUCAST-and CLSI potency NEO-SENSITABSTM (Rosco Diagnostica A/S, Taastrup, Denmark) according to the manufacturer’s instructions.

Techniques: Biomarker Discovery, Infection

Baseline characteristics and diarrheic symptoms at inclusion for per-protocol population allocated to either azithromycin or placebo. For continuous variables, 95% confidence intervals are presented in parentheses following mean values.

Journal: PLoS ONE

Article Title: Azithromycin vs. Placebo for the Clinical Outcome in Campylobacter concisus Diarrhoea in Adults: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

doi: 10.1371/journal.pone.0166395

Figure Lengend Snippet: Baseline characteristics and diarrheic symptoms at inclusion for per-protocol population allocated to either azithromycin or placebo. For continuous variables, 95% confidence intervals are presented in parentheses following mean values.

Article Snippet: Antimicrobial susceptibility testing to azithromycin was performed with use of disk diffusion with 15μg azithromycin using EUCAST-and CLSI potency NEO-SENSITABSTM (Rosco Diagnostica A/S, Taastrup, Denmark) according to the manufacturer’s instructions.

Techniques: